There is increasing evidence that AD progression differs by sex.
Objective:
The aim of this work was to determine sex differences in the association of baseline levels of cerebrospinal fluid (CSF) biomarkers (Aβ42, p-tau, YKL-40, sTREM2) with longitudinal brain changes in cognitively unimpaired (CU) older adults.
Methods:
This pilot study included 36 CU subjects (age 66.5±5.5, 12 male) scanned twice, two years apart. Using a voxel-wise analysis, we determined the sex differences in the association maps between CSF biomarkers and atrophy rates.
Results:
We did not find differences related to Aβ42. We found a greater impact of the rest of CSF biomarkers in areas of the Papez circuit in women versus men. Men showed greater involvement in lateral parietal and paracentral areas.
Discussion:
Results suggest an early differential progression of brain atrophy between sexes. Further research will elucidate whether the mechanisms responsible for sex-specific atrophy patterns are biological and/or environmental.
Alzheimer’s Association (2016) 2016 Alzheimer’s disease facts and figures. Alzheimers Dement12, 459–509.
2.
FerrettiMT, IulitaMF, CavedoE, ChiesaPA, Schumacher DimechA, Santuccione ChadhaA, BaracchiF, GirouardH, MisochS, GiacobiniE, DepypereH, HampelH, Initiative for the WBP and the APM (2018) Sex differences in Alzheimer disease — the gateway to precision medicine. Nat Rev Neurol14, 457–469.
3.
NebelRA, AggarwalNT, BarnesLL, GallagherA, GoldsteinJM, KantarciK, MallampalliMP, MorminoEC, ScottL, YuWH, MakiPM, MielkeMM (2018) Understanding the impact of sex and gender in Alzheimer’s disease: A call to action. Alzheimers Dement14, 1171–1183.
4.
SnyderHM, AsthanaS, BainL, BrintonR, CraftS, DubalDB, EspelandMA, GatzM, MielkeMM, RaberJ, RappPR, YaffeK, CarrilloMC (2016) Sex biology contributions to vulnerability to Alzheimer’s disease: A think tank convened by the Women’s Alzheimer’s Research Initiative. Alzheimers Dement12, 1186–1196.
5.
MedeirosADM, SilvaRH (2019) Sex differences in Alzheimer’s disease: Where do we stand?J Alzheimers Dis67, 35–60.
6.
LinKA, ChoudhuryKR, RathakrishnanBG, MarksDM, PetrellaJR, DoraiswamyPM (2015) Marked gender differences in progression of mild cognitive impairment over 8 years. Alzheimers Dement (N Y)1, 103–110.
7.
BeamCR, KaneshiroC, JangJY, ReynoldsCA, PedersenNL, GatzM (2018) Differences between women and men in incidence rates of dementia and Alzheimer’s disease. J Alzheimers Dis64, 1077–1083.
8.
JackCR, WisteHJ, WeigandSD, TherneauTM, KnopmanDS, LoweV, VemuriP, MielkeMM, RobertsRO, MachuldaMM, SenjemML, GunterJL, RoccaWA, PetersenRC (2017) Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: A cross-sectional study. Lancet Neurol16, 435–444.
9.
BuckleyRF, MorminoEC, RabinJS, HohmanTJ, LandauS, HanseeuwBJ, JacobsHIL, PappKV, AmariglioRE, ProperziMJ, SchultzAP, KirnD, ScottMR, HeddenT, FarrellM, PriceJ, ChhatwalJ, RentzDM, VillemagneVL, JohnsonKA, SperlingRA (2019) Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults. JAMA Neurol76, 542–551.
HuaX, HibarDP, LeeS, TogaAW, JackCR, WeinerMW, ThompsonPM (2010) Sex and age differences in atrophic rates: An ADNI study with=1368 MRI scans. Neurobiol Aging31, 1463–80.
12.
SkupM, ZhuH, WangY, GiovanelloKS, LinJA, ShenD, ShiF, GaoW, LinW, FanY, ZhangH (2011) Sex differences in grey matter atrophy patterns among AD and aMCI patients: Results from ADNI. Neuroimage56, 890–906.
13.
Bonneh-BarkayD, WangG, StarkeyA, HamiltonRL, WileyCA (2010) In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation7, 1–8.
TakahashiK, RochfordCDP, NeumannH (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med201, 647–657.
17.
UlrichJD, UllandTK, ColonnaM, HoltzmanDM (2017) Elucidating the role of TREM2 in Alzheimer’s disease. Neuron94, 237–248.
18.
KleinbergerG, YamanishiY, Suárez-CalvetM, CzirrE, LohmannE, CuyversE, StruyfsH, PettkusN, Wenninger-WeinzierlA, MazaheriF, TahirovicS, LleóA, AlcoleaD, ForteaJ, WillemM, LammichS, MolinuevoJL, Sánchez-ValleR, AntonellA, RamirezA, HenekaMT, SleegersK, Van Der ZeeJ, MartinJJ, EngelborghsS, Demirtas-TatlidedeA, ZetterbergH, Van BroeckhovenC, GurvitH, Wyss-CorayT, HardyJ, ColonnaM, HaassC (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med6, 243ra86.
19.
HickmanSE, KingeryND, OhsumiTK, BorowskyML, WangLC, MeansTK, El KhouryJ (2013) The microglial sensome revealed by direct RNA sequencing. Nat Neurosci16, 1896–1905.
20.
Suárez-CalvetM, KleinbergerG, Araque CaballeroMÁ, BrendelM, RomingerA, AlcoleaD, ForteaJ, LleóA, BlesaR, GispertJD, Sánchez-ValleR, AntonellA, RamiL, MolinuevoJL, BrosseronF, TraschützA, HenekaMT, StruyfsH, EngelborghsS, SleegersK, Van BroeckhovenC, ZetterbergH, NellgårdB, BlennowK, CrispinA, EwersM, HaassC (2016) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer’s disease and associate with neuronal injury markers. EMBO Mol Med8, e201506123.
21.
Suárez-calvetM, Araque CaballeroMÁ, KleinbergerG, BatemanRJ, FaganAM, MorrisJC, LevinJ, DanekA, EwersM, HaassC (2017) Early changes in CSF sTREM2 in dominantly inherited Alzheimer’s disease occur after amyloid deposition and neuronal injury. Sci Transl Med8, 1–24.
22.
Monté-RubioGC, FalcónC, Pomarol-ClotetE, AshburnerJ (2018) A comparison of various MRI feature types for characterizing whole brain anatomical differences using linear pattern recognition methods. Neuroimage178, 753–768.
23.
FalconC, Monté-RubioGC, Grau-RiveraO, Suárez-CalvetM, Sánchez-ValleR, RamiL, BoschB, HaassC, GispertJD, MolinuevoJL (2019) CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. Neuroimage Clin23, 101801.
24.
BuschkeH, KuslanskyG, KatzM, StewartWF, SliwinskiMJ, EckholdtHM, LiptonRB (1999) Screening for dementia with the memory impairment screen. Neurology52, 231–238.
25.
GramuntN, BuschkeH, Sànchez-BenavidesG, LiptonRB, Peña-CasanovaJ, Diéguez-VideF, MasramonX, GispertJd, FauriaK, CamíJ, MolinuevoJL (2015) Reference data of the Spanish memory binding test in a midlife population from the ALFA STUDY (Alzheimer’s and Family). J Alzheimers Dis48, 613–625.
26.
AntonellA, ForteaJ, RamiL, BoschB, BalasaM, Sánchez-ValleR, IranzoA, MolinuevoJL, LladóA (2011) Different profiles of Alzheimer’s disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. J Neural Transm118, 259–262.
27.
FjellAM, WalhovdKB, Fennema-NotestineC, McEvoyLK, HaglerDJ, HollandD, BlennowK, BrewerJB, DaleAM, Alzheimer’s Disease Neuroimaging Initiative (2010) Brain atrophy in healthy aging is related to CSF levels of Aβ1–42. Cereb Cortex20, 2069–2079.
28.
MattssonN, AndreassonU, PerssonS, CarrilloMC, CollinsS, ChalbotS, CutlerN, Dufour-RainfrayD, FaganAM, HeegaardNHH, Robin HsiungGY, HymanB, IqbalK, KaeserSA, LachnoDR, LleóA, LewczukP, MolinuevoJL, ParchiP, RegeniterA, RissmanRA, RosenmannH, SancesarioG, SchröderJ, ShawLM, TeunissenCE, TrojanowskiJQ, VandersticheleH, VandijckM, VerbeekMM, ZetterbergH, BlennowK, Alzheimer’s Association QC Program Work Group (2013) CSF biomarker variability in the Alzheimer’s Association quality control program. Alzheimers Dement9, 251–261.
29.
AshburnerJ, RidgwayGR (2013) Symmetric diffeomorphic modeling of longitudinal structural MRI. Front Neurosci6, 1–19.
30.
AshburnerJ (2007) A fast diffeomorphic image registration algorithm. Neuroimage38, 95–113.
31.
FalconC, TucholkaA, Monté-RubioGC, CacciagliaR, OpertoG, RamiL, GispertJD, MolinuevoJL (2018) Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer’s disease: A study of two independent datasets. Neuroimage Clin19, 190–201.
Tzourio-MazoyerN, LandeauB, PapathanassiouD, CrivelloF, EtardO, DelcroixN, MazoyerB, JoliotM (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage15, 273–289.
34.
HuaK, ZhangJ, WakanaS, JiangH, LiX, ReichDS, CalabresiPA, PekarJJ, van ZijlPCM, MoriS (2008) Tract probability maps in stereotaxic spaces: Analyses of white matter anatomy and tract-specific quantification. Neuroimage39, 336–347.
35.
MarkowitschHJ (2013) Memory and self–neuroscientific landscapes. ISRN Neurosci2013, 1–26.
36.
BrownCA, JohnsonNF, Anderson-MooneyAJ, JichaGA, ShawLM, TrojanowskiJQ, Van EldikLJ, SchmittFA, SmithCD, GoldBT (2017) Development, validation and application of a new fornix template for studies of aging and preclinical Alzheimer’s disease. Neuroimage Clin13, 106–115.
37.
ArdekaniBA, ConvitA, BachmanAH (2016) Analysis of the MIRIAD data shows sex differences in hippocampal atrophy progression. J Alzheimers Dis50, 847–857.
38.
ApostolovaLG, DinovID, DuttonRA, HayashiKM, TogaAW, CummingsJL, ThompsonPM (2006) 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer’s disease. Brain129, 2867–2873.
39.
JackCRJr, WisteHJ, WeigandSD, RoccaWA, KnopmanDS, MielkeMM, LoweVJ, SenjemML, GunterJL, PreboskeGM, PankratzVS, VemuriP, PetersenRC (2014) Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: A cross-sectional study. Lancet Neurol13, 997–1005.
